comparemela.com

Latest Breaking News On - Nasdaq cyad - Page 1 : comparemela.com

Celyad Oncology (NASDAQ:CYAD) Shares Pass Above Fifty Day Moving Average of $0 69

Celyad Oncology SA (NASDAQ:CYAD – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.69 and traded as high as $0.81. Celyad Oncology shares last traded at $0.75, with a volume of 8,985 shares. Celyad Oncology Stock Down 5.1 […]

Celyad oncology company profileCelyad oncologyGet free reportOncology stock downCelyad oncology dailyNasdaq cyad

Celyad Oncology Reports First Half 2023 Financial Results

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement.

United statesCity ofUnited kingdomWalloon regionWaals gewestMont saint guibertRegion flamandeCaroline lonezGeorges rawadiDavid georgesWorld oncology cell therapy congressInternational conference on lymphocyte engineeringWrd communicationsBusiness developmentExchange commissionDartmouth college

Celyad Oncology to announce full year 2022 financial

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company.

Mont saint guibertWaals gewestNew yorkUnited statesDavid georgesCaroline lonezExchange commissionBusiness developmentWrd communicationsBelgium fixedBelgium mobilePrivate securities litigation reform actCelyad oncologyAnnual reportOncology contactsNasdaq cyad

Celyad Oncology Announces FDA Lifts Clinical Hold of

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company.

United statesMont saint guibertWaals gewestNew yorkWalloon regionSara zelkovicCharles morrisMerck co incExchange commissionCommunications investor relationsMerck sharp dohmeDrug administrationChief medical officerMerck sharpPrivate securities litigation reform actCelyad oncology

Celyad Oncology to Announce First Half 2022 Financial

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company.

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionLincoln parkSara zelkovicLincoln park capital fundExchange commissionCommunications investor relationsCelyad oncologyPrivate securities litigation reform actAnnual reportMedia contactsNasdaq cyadElyad oncology sa

vimarsana © 2020. All Rights Reserved.